Diligence memo · auto-generated · as of July 2, 2026
Lsc-Bio Hc1, Dst
Lsc-Bio Hc1, Dst looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Lsc-Bio Hc1, Dst operates in Biotechnology, based in RADNOR.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lsc-Bio Hc1, Dst has raised $4.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.5M on 2017-11-29.
Most recent recorded round closed around 2017-11-29.
Valuation (modeled)modeled
Provath models Lsc-Bio Hc1, Dst at approximately $161M (range $4.9M–$875M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.76× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era. Within the normal band (76% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 8.6 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 41% of Biotechnology peers (4293 compared).
Modeled value ranks above 68% of those peers.
Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Cynvec LLC, Biothera Holding Corp., Limelight Bio, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.